EVALUATION OF TRANSPLANT BENEFITS WITH THE U.S. SCIENTIFIC REGISTRY OF TRANSPLANT RECIPIENTS BY SEMIPARAMETRIC REGRESSION OF MEAN RESIDUAL LIFE

BY GE ZHAO[1,a], YANYUAN MA[2,b], HUAZHEN LIN[3,c] AND YI LI[4,d]

[1]*Department of Mathematics and Statistics, Portland State University,* [a]*gzhao@pdx.edu*
[2]*Department of Statistics, Pennsylvania State University,* [b]*yzm63@psu.edu*
[3]*Center of Statistical Research, Southwestern University of Finance and Economics,* [c]*linhz@swufe.edu.cn*
[4]*Department of Biostatistics, University of Michigan, Ann Arbor,* [d]*yili@umich.edu*

Kidney transplantation is the most effective renal replacement therapy for end stage renal disease patients. With the severe shortage of kidney supplies and for the clinical effectiveness of transplantation, patient's life expectancy posttransplantation is used to prioritize patients for transplantation; however, severe comorbidity conditions and old age are the most dominant factors that negatively impact posttransplantation life expectancy, effectively precluding sick or old patients from receiving transplants. It would be crucial to design objective measures to quantify the transplantation benefit by comparing the mean residual life with and without a transplant, after adjusting for comorbidity and demographic conditions. To address this urgent need, we propose a new class of semiparametric covariate-dependent mean residual life models. Our method estimates covariate effects semiparametrically efficiently and the mean residual life function nonparametrically, enabling us to predict the residual life increment potential for any given patient. Our method potentially leads to a more fair system that prioritizes patients who would have the largest residual life gains. Our analysis of the kidney transplant data from the U.S. Scientific Registry of Transplant Recipients also suggests that a single index of covariates summarize well the impacts of multiple covariates, which may facilitate interpretations of each covariate's effect. Our subgroup analysis further disclosed inequalities in survival gains across groups defined by race, gender and insurance type (reflecting socioeconomic status).

1. Introduction. About 15% of American adults have chronic kidney disease (Saran et al. (2016)), suffering worsened kidney functions, with less fluid filtrated by the glomerular, and losing kidney functions gradually but permanently over the cause of months or years. According to the glomerular filtration rate (GFR), chronic kidney disease is classified into five stages, where stage four (GFR between 15 and 29 ml/min/$1.73m^2$) and stage five (GFR less than 15 ml/min/$1.73m^2$) kidney diseases are considered to be end-stage renal disease (ESRD), one of the most lethal diseases globally (Feng et al. (2019), Ferri (2017)). In the U.S., more than 600,000 individuals are living with ESRD, about 100,000 new ESRD cases are diagnosed and 50,000 deaths occur each year (Salerno et al. (2021)).

The most common treatment for ESRD is renal replacement therapy, including dialysis and kidney transplant. As dialysis only provides partial kidney functions, dialysis patients tend to have shorter survival than those receiving kidney transplants, which often lead to a longer and a better quality of life (Evans et al. (1985), Liem et al. (2007), Wolfe et al. (1999)). Due to severe shortages in kidney supplies, however, there are far more ESRD patients who need kidney transplants than donors available in the U.S. (Tonelli et al. (2011)). For example, the U.S. Scientific Registry of Transplant Recipients (SRTR) reports that among 247,123 patients

awaiting kidney transplants during 2011–2018, only 139,270 patients actually received one, leaving the remaining 107,853 still waiting (Hart et al. (2021)).

Currently, decisions on patients' priority of receiving kidney transplants are based on the estimated posttransplant survival (EPTS) score, which predicts a patient's life expectancy post transplantation by using a Cox model with age, diabetes status, prior solid organ transplant and time on dialysis as predictors (Time (2012)). Preexisting conditions, such as diabetes, prior solid organ transplants and long dialysis vintage, are associated with shorter survival (Cosio et al. (1998), Kasiske et al. (2001), Meier-Kriesche et al. (2000)); thus, patients with these conditions tend to have a lower priority for transplantation (Cosio et al. (1998), Molnar et al. (2011)). On the other hand, younger age is found to be associated with better outcomes and younger patients are likely to have a higher priority for transplantation. Thus, age and severe comorbidity conditions have effectively become the most dominant factors when deciding on who to receive transplants, which may preclude older and sicker patients from benefiting from transplantation (Gore et al. (2009), Jassal, Schaubel and Fenton (2005), Weng et al. (2010)). A more comprehensive system, however, should give a higher priority to those who would benefit more from transplantation among patients with similar conditions, and in the meantime, triage candidates may gain little or even suffer a loss in life expectancy. We propose to quantify the transplant benefit by comparing the improvement of the patient's expected residual life with and without transplantation. The expected residual life characterizes the mean of the remaining survival time, given that a patient has survived up to a certain time (Hall and Wellner (1981)). Compared to overall survival, the residual life expectancy provides a real time assessment of transplant benefits at any given time when a kidney becomes available (Lin, Fei and Li (2016)). As demographic and clinical conditions may be confounders affecting survival and should be adjusted for when assessing transplant benefits (Carrero et al. (2018), Cosio et al. (1998)), we aim at modeling and evaluating a patient's potential residual life expectancy, with or without transplant, based on the patient's covariate profile.

Much work on mean residual life models has been sparked by Oakes and Dasu (1990). For example, Maguluri and Zhang (1994) proposed a univariate proportional mean residual life model; Oakes and Dasu (2003) established the theoretical properties of the methods in Oakes and Dasu (1990); Chen and Cheng (2005) estimated the coefficients of covariates in a proportional mean residual life model by a partial-score approach, analogous to the partial-likelihood approach; Chen et al. (2005) employed the inverse probability weighting approach for inference; Müller and Zhang (2005) extended the mean residual life model to incorporate time-varying covariates; Chen and Cheng (2006) proposed an extended Buckley–James estimator to estimate a linear residual life model, and Chen (2007) further proposed an additive mean residual life model. These works inspired median and quantile residual life models; see, for example, Jeong, Jung and Costantino (2008), Jung, Jeong and Bandos (2009), Ma and Yin (2010) and Ma and Wei (2012). However, all these works imposed parametric dependency of residual life on covariates as well as how long the patient has lived up to transplantation (or "alive time" hereafter). Violations of the model assumptions will lead to biased estimates and incorrect inferences (Chen (2007), Chen et al. (2005)). Our preliminary analysis of the kidney transplant data from SRTR indicates that the mean residual life depends on alive time and patients' other covariates, such as treatment history, commorbidty conditions and demographics, through a complicated form which is challenging to model parametrically.

We propose a new class of semiparametric mean residual life models, with the goal of detecting the effects of patients' covariates on the residual life and identifying the patients who may benefit most from transplantation. Our model does not impose any parametric assumptions on the mean residual life function and, thus, the hazard function, and extends the model in Ma and Zhu (2012) and Ma and Zhu (2013) to accommodate censoring in response.

Moreover, given multiple covariates, we also propose a flexible dimension reduction method to achieve a parsimonious model for efficiency and interpretability. To derive the estimators, we employ a semiparametric method in combination with a martingale treatment, as in Zhao, Ma and Lu (2022), to derive a semiparametrically efficient estimator (Bickel et al. (1993)) for the effects of covariates and an asymptotically normally distributed nonparametric estimator of the mean residual life function. We apply the proposed method to analyze the SRTR kidney transplant data and quantify transplantation gains by using the residual life expectancy. Our analysis suggested that a single index of covariates summarize well the impacts of multiple covariates, which may facilitate interpretations of each covariate's effect. Our subgroup analysis further disclosed inequalities in survival gains across groups defined by race, gender and insurance type (reflecting socioeconomic status). The results may inform the priority rules for kidney transplantation.

This paper is organized as follows. Section 2 proposes the mean residual life model, and Section 3 derives the estimators for the proposed model and discusses their properties. We assess the finite sample properties of the methods by simulation studies in Section 5 and apply it to analyze the kidney transplant data in Section 6. We conclude the paper with some discussions in Section 7. We defer the regularity conditions and technical properties to the Supplementary Material (Zhao et al. (2024)).

2. Semiparametric regression of mean residual life. Denote by T the potential time lag from being waitlisted for transplantation (i.e., became eligible) to death in the absence of censoring and by $\mathbf{X} \in \mathcal{R}^p$ the baseline covariates, such as age, diabetes status, and prior solid organ transplant, measured at the waitlisting time. Denote by W the time lag from waitlisting to hypothetical transplant time that would have occurred in the absence of censoring. Our focus is to model the difference of the mean residual life, with and without transplant, at any time point t, given $\mathbf{X}$ and W observed up to t.

Let the indicator function $I(W \le t)$ describe the time-dependent transplant status, with $I(W \le t) = 0$ and 1 corresponding to "Nontransplant" and "Transplant" at time t, respectively. Following the missing data literature, we use $WI(W \le t)$ to indicate the value of W *only* when the transplant occurs before t. Given the history of transplantation status up to time t, that is, $\{I(W \le t), WI(W \le t)\}$, we specify that the conditional hazard at t depends only on the transplantation information at t, that is,

(1)
$$\lim_{h \to 0^+} h^{-1} P\{t \le T \le t + h | T \ge t, \mathbf{X}, I(W \le t), WI(W \le t)\}$$
$$= \lambda\{t, \mathbf{X}, I(W \le t), WI(W \le t)\}$$
$$= \lambda_T(t - W, \mathbf{X}, W)I(W \le t) + \lambda_N(t, \mathbf{X})\{1 - I(W \le t)\},$$

where the subscripts "$_T$" and "$_N$," respectively, stand for "Transplant" and "Nontransplant." Within the nontransplant group by time t, that is, $W > t$, the hazard function depends on the time and covariates only; at and after transplantation, that is, $W \le t$, the hazard function is to be reset and is a function of $t - W$ (the time lag since transplantation) because of immediate surgical risks (Hernandez et al. (2006), Humar and Matas (2005)) and long term benefits of receiving functional organs (Lin, Fei and Li (2016)). Additionally, W is considered as an influential factor in λ_T because, for example, there is a clear survival advantage in favor of preemptive kidney transplantation (Liem and Weimar (2009)).

A naive mean residual life (Maguluri and Zhang (1994)) would have been computed as $E(T - t | T \ge t, \mathbf{X}, W)$. However, the conditioning part of this expectation looks beyond t for a prospective $W > t$, which is problematic as a patient would be guaranteed to survive at least up to W when $W > t$, coinciding with the notion that one cannot directly use time dependent treatment or, more broadly, "internal" time dependent covariates to predict survival

(Kalbfleisch and Prentice (1980)). Instead, at each time t, we compute the mean residual life based on the hazard (1) that strictly conditions on the information available by then, that is,

$$
\begin{aligned}
(2) \quad & E\big(T - t \mid T \geq t, \mathbf{X}, I(W \leq t), W I(W \leq t)\big) \\
& = e^{\Lambda_T(t - W, \mathbf{X}, W)} \int_{t-W}^{\infty} e^{-\Lambda_T(s, \mathbf{X}, W)} \, ds \, I(W \leq t) + e^{\Lambda_N(t, \mathbf{X})} \\
& \quad \times \int_t^{\infty} e^{-\Lambda_N(s, \mathbf{X})} \, ds \{1 - I(W \leq t)\},
\end{aligned}
$$

and will draw inference based on this valid model. Here $\Lambda_N(t, \mathbf{X}) = \int_0^t \lambda_N(s, \mathbf{X}) \, ds$ and $\Lambda_T(t, \mathbf{X}, W) = \int_0^t \lambda_T(s, \mathbf{X}, W) \, ds$ are the two cumulative hazard functions. This model uses the "baseline" information at time t only (i.e., no look beyond t) to project future survival; see details in Section 1 of the Supplementary Material (Zhao et al. (2024)).

For ease of notation, we rewrite (2) as $m\{t, \mathbf{X}, I(W \leq t), W I(W \leq t)\} = m_T(t - W, \mathbf{X}, W) I(W \leq t) + m_N(t, \mathbf{X})\{1 - I(W \leq t)\}$, where

$$
m_T(t, \mathbf{X}, W) = e^{\Lambda_T(t, \mathbf{X}, W)} \int_t^{\infty} e^{-\Lambda_T(s, \mathbf{X}, W)} \, ds
$$

and

$$
m_N(t, \mathbf{X}) = e^{\Lambda_N(t, \mathbf{X})} \int_t^{\infty} e^{-\Lambda_N(s, \mathbf{X})} \, ds,
$$

which may facilitate evaluation of the benefits of transplant at any given time. Particularly, $m_T(t - W, \mathbf{X}, W) - m_N(t, \mathbf{X})$ quantifies the gain (or loss) of life expectancy of patients at t with a transplant given at $W < t$ compared with those who would never receive a transplant; candidates with close to zero or a negative value of $m_T(t - W, \mathbf{X}, W) - m_N(t, \mathbf{X})$ would benefit little from organ transplantation and would have lower priorities in the waiting list (Chadban et al. (2020)). This formulation suits the organ transplant setting: the severe shortage of organs restricts the sources of donations and obliges us to compare the situation where an immediate donation is received with the situation where donation is impossible at all.

To ensure estimability, we make a complete follow-up assumption (Chen and Cheng (2005), Chen et al. (2005), Sun and Zhang (2009), Tsiatis (1990)), that is, the failure time T is supported on a finite range $(0, \tau)$ with $\tau < \infty$, where, in practice, τ is the maximum follow-up time; we relax this assumption in Supplementary Material 5 (Zhao et al. (2024)). We further assume the covariates $\mathbf{X}$ affect T via index $\boldsymbol{\beta}$, where $\boldsymbol{\beta} \in \mathcal{R}^{p \times d}$ is the coefficient matrix with $d \leq p$. Then (1) and (2) can, respectively, be expressed as

$$
\begin{aligned}
(3) \quad & \lambda\{t, \mathbf{X}, I(W \leq t), W I(W \leq t)\} \\
& = \lambda_T(t - W, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}, W) I(W \leq t) + \lambda_N(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X})\{1 - I(W \leq t)\},
\end{aligned}
$$

$$
\begin{aligned}
(4) \quad & m\{t, \mathbf{X}, I(W \leq t), W I(W \leq t)\} \\
& = m_T(t - W, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}, W) I(W \leq t) + m_N(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X})\{1 - I(W \leq t)\},
\end{aligned}
$$

where λ_T, λ_N, m_T and m_N are unspecified positive functions, which need to be estimated. The model stipulates that the conditional mean of $T - t$ depends on $\mathbf{X}$ via its d indices, formed by projecting $\mathbf{X}$ to the columns of $\boldsymbol{\beta}$, and the waiting time W. When $d = 1$, the model reduces to a single index model in terms of $\mathbf{X}$; when $1 < d < p$, it corresponds to a dimension reduction structure; when $d = p$, the model is completely nonparametric. Our analysis first focuses on a fixed d, followed by selecting d in a data driven fashion, as discussed in Section 6. Model (4) is general: it includes the proportional mean residual life model, that is, $m\{t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}, I(W \leq t), W I(W \leq t)\} = m_0(t) \exp(\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X})$ (Oakes and Dasu (1990)) as a special case by specifying $m_N\{t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}\} = m_0(t)e^{\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}}$, $m_T\{t - W, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}, W\} = m_0(t)e^{\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X} + \alpha W}$

with $\alpha = 0$ and $d = 1$; it reduces to the additive model $m_0(t) + \boldsymbol{\beta}^T\mathbf{X}$ (Chen (2007)) by specifying $m_N\{t, \boldsymbol{\beta}^T\mathbf{X}\} = m_0(t) + \boldsymbol{\beta}^T\mathbf{X}$, $m_T\{t - W, \boldsymbol{\beta}^T\mathbf{X}, W\} = m_0(t) + \boldsymbol{\beta}^T\mathbf{X} + \alpha W$ with $\alpha = 0$ and setting $d = 1$. By allowing d to be larger than 1, model (4) extends these classical models by allowing more flexible forms, such as $m\{t, \boldsymbol{\beta}^T\mathbf{X}, I(W \leq t), WI(W \leq t)\} = m_0(t)\{\sum_{k=1}^d \exp(\boldsymbol{\beta}_{\cdot,k}^T\mathbf{X})\}$ and $m\{t, \boldsymbol{\beta}^T\mathbf{X}, I(W \leq t), WI(W \leq t)\} = m_0(t) + \sum_{k=1}^d \boldsymbol{\beta}_{\cdot,k}^T\mathbf{X}$, where $\boldsymbol{\beta}_{\cdot,k}$ is the kth column of $\boldsymbol{\beta}$. These special cases implicitly assume that transplant or the timing of transplantation does not impact survival.

We further assume that T is subject to random right censoring so that $C \perp\!\!\!\perp T | W, \mathbf{X}$, where C is the censoring time, and we observe $Z = \min(T, C)$ and $\Delta = I(T \leq C)$. In our dataset, W (or transplant) can only be observed while the patient is still at risk, that is, before death or censoring occurs. We assume the observed $\{\mathbf{X}_i, Z_i, \Delta_i, I(W_i \leq Z_i), W_i I(W_i \leq Z_i)\}$, $i = 1, \ldots, n$ be independently and identically distributed realizations of $\{\mathbf{X}, Z, \Delta, I(W \leq Z), WI(W \leq Z)\}$. This notation stipulates that W is subject to censoring, due to Z, with an indicator of $I(W \leq Z)$. To make (4) identifiable and estimable, we fix the upper $d \times d$ block of $\boldsymbol{\beta}$ to be $\mathbf{I}_d$ and estimate the lower $(p - d) \times d$ block of $\boldsymbol{\beta}$. Corresponding to the upper and lower parts of $\boldsymbol{\beta}$, we write $\mathbf{X} = (\mathbf{X}_u^T, \mathbf{X}_l^T)^T$, where $\mathbf{X}_u \in \mathcal{R}^d$ and $\mathbf{X}_l \in \mathcal{R}^{p-d}$.

3. A semiparametrically efficient estimator.

Denote the conditional survival function, cumulative hazard function, hazard function and probability density function of the censoring time C by $S_c(z, \mathbf{X}) = \text{pr}(C \geq z|\mathbf{X})$, $\Lambda_c(z, \mathbf{X}) = -\log S_c(z, \mathbf{X})$, $\lambda_c(z, \mathbf{X}) = \partial\Lambda_c(z, \mathbf{X})/\partial z$ and $f_c(z, \mathbf{X}) = -\partial S_c(z, \mathbf{X})/\partial z$ with $z < \tau$, where $0 < \tau < \infty$ is the upper bound of the follow-up time. Let $p(\mathbf{X}) \equiv \text{pr}(C = \tau|\mathbf{X})$, and it follows that $S_c(\tau, \mathbf{X}) = f_c(\tau, \mathbf{X}) = p(\mathbf{X})$, and $\lambda_c(\tau, \mathbf{X}) = 1$. Here $\lambda_c(z, \mathbf{X})$ and $f_c(z, \mathbf{X})$ are absolutely continuous on $(0, \tau)$ but with a discontinuity point at τ.

To estimate $m_T(t - W, \boldsymbol{\beta}^T\mathbf{X}, W) - m_N(t, \boldsymbol{\beta}^T\mathbf{X})$, which quantifies the gain (or loss) of mean residual life after t with transplant given at $W \leq t$, we need to estimate $\boldsymbol{\beta}$ and the functionals of m_T and m_N for which we consider a likelihood-based approach.

Under independent censoring the joint partial probability density function [for mixed random variables (Casella and Berger (2001))] of $\{\mathbf{X}, Z, \Delta, WI(W \leq Z)\}$, conditional on a random variable $I(W \leq Z)$, is

$$f_{\mathbf{X},Z,\Delta,WI(W\leq Z)|I(W\leq Z)}\{\mathbf{x}, z, \delta, wI(w \leq z)|I(w \leq z)\}$$

$$
\begin{aligned}
(5) \quad &= \{\lambda_T(z - w, \boldsymbol{\beta}^T\mathbf{x}, w)\}^\delta e^{-\int_0^w \lambda_N(s, \boldsymbol{\beta}^T\mathbf{x})\,ds - \int_w^z \lambda_T(s-w, \boldsymbol{\beta}^T\mathbf{x}, w)\,ds} \lambda_c(z, \mathbf{x})^{1-\delta} e^{-\int_0^z \lambda_c(s,\mathbf{x})\,ds} \\
&\quad \times f_{\mathbf{X},W|W\leq Z}(\mathbf{x}, w) I(w \leq z) \\
&\quad + \{\lambda_N(z, \boldsymbol{\beta}^T\mathbf{x})\}^\delta e^{-\int_0^z \lambda_N(s, \boldsymbol{\beta}^T\mathbf{x})\,ds} \lambda_c(z, \mathbf{x})^{1-\delta} e^{-\int_0^z \lambda_c(s,\mathbf{x})\,ds} f_{\mathbf{X}|W>Z}(\mathbf{x})\{1 - I(w \leq z)\},
\end{aligned}
$$

where the last equality stems from (1)–(3). We do not need to specify the distribution of $\mathbf{X}|W > Z$ or the joint distribution of $\mathbf{X}, W|W \leq Z$, as our ensuing estimation is conditional on the observed $W, \mathbf{X}$ and $W \leq Z$.

We view the probability function in (5) as a semiparametric model where all unknown components, except for $\boldsymbol{\beta}$, are infinite dimensional nuisance parameters. The parameters $\boldsymbol{\beta}$ are parameters of interest with a finite dimension. We will estimate $\boldsymbol{\beta}$ by using a geometric approach, which avoids decomposing $\lambda(\cdot)$ to be $\lambda_*(z)e^{\boldsymbol{\beta}^T\mathbf{X}}$, as in a proportional hazards model. This entails more flexibility for the model.

Let $Y(t) = I(Z \geq t)$ and $N(t) = I(Z \leq t)\Delta$ be the at-risk and counting process, respectively. Define the filtration $\mathcal{F}_t = \sigma\{N(u), Y(u), \mathbf{X}, I(W \leq u), WI(W \leq u), 0 \leq u < t\}$, and let $M(t) = N(t) - \int_0^t Y(s)\lambda\{s, \boldsymbol{\beta}^T\mathbf{X}, I(W \leq s), WI(W \leq s)\}\,ds$ be the martingale with respect to $\mathcal{F}_t$.

3.1. *Construction of efficient score functions.* Given the regular score by differentiating the joint partial probability density function (5) with respect to $\boldsymbol{\beta}$, an efficient score, as derived in Supplementary Material 2.1 (Zhao et al. (2024)), is

$$
\begin{aligned}
&\mathbf{S}_{\text{eff}}\{\Delta, Z, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq Z), WI(W \leq Z)\} \\
&= \int_0^\infty \Bigg\{ \frac{\mathbf{m}_{12}\{s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\}}{m_1\{s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\} + 1} \\
&\qquad - \frac{\mathbf{m}_2\{s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\}}{m(s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s))} \Bigg\} \\
&\qquad \otimes \left[\mathbf{X}_l - \frac{E\{\mathbf{X}_l S_c(s, \mathbf{X}) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}\}}{E\{S_c(s, \mathbf{X}) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}\}} \right] dM\{s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\},
\end{aligned}
$$
(6)

where $m_1(s, \mathbf{v}, \cdot, \cdot) \equiv \partial m(s, \mathbf{v}, \cdot, \cdot)/\partial s$, $\mathbf{m}_2(s, \mathbf{v}, \cdot, \cdot) \equiv \partial m(s, \mathbf{v}, \cdot, \cdot)/\partial \mathbf{v}$, $\mathbf{m}_{12}(s, \mathbf{v}, \cdot, \cdot) \equiv \partial \mathbf{m}_2\{s, \mathbf{v}, \cdot, \cdot\}/\partial s$, and $\mathbf{X}_l$ is the lower $p - d$ components in $\mathbf{X}$.

3.2. *Construction of semiparametrically efficient estimator of $\boldsymbol{\beta}$.* A consistent estimating equation can be obtained from $E[\mathbf{S}_{\text{eff}}\{\Delta, Z, \mathbf{X}, I(W \leq Z), WI(W \leq Z)\}|\mathbf{X}] = \mathbf{0}$, as the integrand in the above integral is predictable and $M\{s, \boldsymbol{\beta}_0^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\}$ is a martingale. Hence, to preserve the mean zero property and to simplify the computation, we can replace the part in the form of $\mathbf{m}_{12}/(m_1 + 1) - \mathbf{m}_2/m$ within the curly brackets in (6) by an arbitrary function of s, $\boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}$, $I(W \leq s)$ and $WI(W \leq s)$, say $\mathbf{g}\{s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\}$, and still obtain

$$
\begin{aligned}
E\Bigg(\int_0^\infty &\mathbf{g}\{s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\} \\
&\otimes \left[\mathbf{X}_l - \frac{E\{\mathbf{X}_l S_c(s, \mathbf{X}) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}\}}{E\{S_c(s, \mathbf{X}) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}\}} \right] dM\{s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\} \Bigg) = \mathbf{0}.
\end{aligned}
$$

This provides a richer class of estimators than the estimator based on $\mathbf{S}_{\text{eff}}$ alone. For example, assigning a simple $\mathbf{g}\{s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\}$ yields a useful estimating equation whose solution is consistent and often easy to get due to its simplicity. It is usually adopted as an initial value for the efficient estimator proposed later to avoid local solutions in the finite sample situations.

The fraction within the square brackets in (6) satisfies, when $t \leq \tau$,

$$
\frac{E\{\mathbf{X}_l S_c(t, \mathbf{X}) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}\}}{E\{S_c(t, \mathbf{X}) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}\}} = \frac{E\{\mathbf{X}_l Y(t) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq t), WI(W \leq t)\}}{E\{Y(t) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq t), WI(W \leq t)\}};
$$
(7)

see Supplement 2.1.2 (Zhao et al. (2024)) for further discussion at the tail when $t > \tau$. We then verify that

$$
\begin{aligned}
E\Bigg(\int_0^\infty &\mathbf{g}\{s, \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}, I(W \leq s), WI(W \leq s)\} \\
&\otimes \left[\mathbf{X}_l - \frac{E\{\mathbf{X}_l S_c(s, \mathbf{X}) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}\}}{E\{S_c(s, \mathbf{X}) | \boldsymbol{\beta}_0{}^{\text{T}}\mathbf{X}\}} \right] dN(s) \Bigg) = \mathbf{0}.
\end{aligned}
$$
(8)

Note that (7) and (8), proved in Supplementary Material 2.1.2 (Zhao et al. (2024)), imply that we can construct estimating equations that depend on the transplantation status as follows:

$$
\begin{aligned}
(9) \quad & \sum_{i=1}^{n} \Delta_i \mathbf{g}\{Z_i, \boldsymbol{\beta}_0^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\} \\
& \otimes \left[\mathbf{X}_{li} - \frac{\widehat{E}\{\mathbf{X}_{li} Y_i(Z_i) | \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}}{\widehat{E}\{Y_i(Z_i) | \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}} \right] = \mathbf{0},
\end{aligned}
$$

where $\mathbf{g}(\cdot)$ is any nonrandom function and $\widehat{E}\{Y_i(Z_i) | \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}$ and $\widehat{E}\{\mathbf{X}_{li} Y_i(Z_i) | \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}$ are given in Supplementary Material 2.2.1 (Zhao et al. (2024)). Here $\widehat{E}\{Y_i(Z_i) | \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\} \equiv \widehat{E}\{Y_i(t) | \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}|_{t=Z_i}$ and similarly for the other terms.

As such, we obtain the efficient estimator of $\boldsymbol{\beta}$ by solving

$$
\begin{aligned}
(10) \quad & \sum_{i=1}^{n} \Delta_i \left[\frac{\widehat{\mathbf{m}}_{12}\{Z_i, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}}{\widehat{m}_1\{Z_i, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\} + 1} \right. \\
& \left. - \frac{\widehat{\mathbf{m}}_2\{Z_i, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}}{\widehat{m}\{Z_i, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}} \right] \\
& \otimes \left[\mathbf{X}_{li} - \frac{\widehat{E}\{\mathbf{X}_{li} Y_i(Z_i) | \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}}{\widehat{E}\{Y_i(Z_i) | \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i, I(W_i \le Z_i), W_i I(W_i \le Z_i)\}} \right] = \mathbf{0},
\end{aligned}
$$

where $\widehat{m}_1(t, \mathbf{v}, \cdot, \cdot), \widehat{\mathbf{m}}_2(t, \mathbf{v}, \cdot, \cdot), \widehat{\mathbf{m}}_{12}(t, \mathbf{v}, \cdot, \cdot)$ are estimators for the derivatives of $m(t, \mathbf{v}, \cdot, \cdot)$ with respect to the first two elements given in Supplementary Material 2.2.1 (Zhao et al. (2024)). The results on efficiency are given in Theorem 2.

3.3. *Nonparametric estimation of mean residual life functions.* We estimate $m\{t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, I(W \le t), W I(W \le t)\}$ nonparametrically via $\widehat{\Lambda}_T\{t - W, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W\} I(W \le t) + \widehat{\Lambda}_N\{t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}\}\{1 - I(W \le t)\}$, based on a kernel smoothed version of the Nelson–Aalen estimator (Ramlau-Hansen (1983), Andersen et al. (1993)). For any t, W (such that $W < t$) and $\boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}$, the estimators, $\widehat{\Lambda}_T\{t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W\}$ and $\widehat{\Lambda}_N\{t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}\}$, have the forms of

$$
\widehat{\Lambda}_T(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W) = \sum_{i=1}^{n} \int_0^t \frac{I(W_i \le s) K_h(\boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i - \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W_i - W)}{\sum_{j=1}^{n} Y_j(s) I(W_j \le s) K_h(\boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_j - \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W_j - W)} dN_i(s),
$$

$$
\widehat{\Lambda}_N(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}) = \sum_{i=1}^{n} \int_0^t \frac{I(W_i > s) K_h(\boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_i - \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X})}{\sum_{j=1}^{n} Y_j(s) I(W_j > s) K_h(\boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}_j - \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X})} dN_i(s),
$$

with a multivariate kernel function $K_h(u_1, u_2, \ldots, u_q) = \prod_{i=1}^{q} K(u_i / h_i) / h_i$, where $h = (h_1, \ldots, h_q)$ is a bandwidth vector and $K(\cdot)$ is a standard univariate kernel function satisfying $K(u) \ge 0$ and $\int_{-\infty}^{\infty} K(u) \, du = 1$ (Wand (1994)).

Following Maguluri and Zhang (1994), we obtain

$$
\begin{aligned}
(11) \quad & \widehat{m}_T(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W) = e^{\widehat{\Lambda}_T(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W)} \int_t^{\infty} e^{-\widehat{\Lambda}_T(s, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W)} \, ds \quad \text{when } W \le t, \\
& \widehat{m}_N(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}) = e^{\widehat{\Lambda}_N(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X})} \int_t^{\infty} e^{-\widehat{\Lambda}_N(s, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X})} \, ds \quad \text{when } W > t.
\end{aligned}
$$

It is worth noting that when computing $\widehat{\Lambda}_T(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W)$ or $\widehat{m}_T(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X}, W)$, we use only the transplanted observations, whereas when computing $\widehat{\Lambda}_N(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X})$ or $\widehat{m}_N(t, \boldsymbol{\beta}^{\mathrm{T}} \mathbf{X})$, we use the full data but censor those who have received the transplant at the transplantation time.

4. Asymptotic properties and semiparametric efficiency. We develop a series of theorems and establish that the estimators of $\boldsymbol{\beta}$ are $\sqrt{n}$-consistent, asymptotically normally distributed and semiparametrically efficient, and the nonparametric estimators, $\widehat{m}_T(t, \boldsymbol{\beta}^T\mathbf{X}, W)$ and $\widehat{m}_N(t, \boldsymbol{\beta}^T\mathbf{X})$ in (11), are asymptotically normally distributed. We defer the required conditions, lemmas and all the proofs to the Supplementary Material (Zhao et al. (2024)):

THEOREM 1. *Under the regularity conditions in Supplementary Material* 4.1 (*Zhao et al.* (2024)), $\widehat{\boldsymbol{\beta}}$, *the estimator obtained by solving* (9) *or* (10), *is consistent, that is,* $\widehat{\boldsymbol{\beta}} - \boldsymbol{\beta} \to \mathbf{0}$ *in probability when* $n \to \infty$.

THEOREM 2. *Under the regularity conditions in Supplementary Material* 4.1 (*Zhao et al.* (2024)), *the estimator,* $\widehat{\boldsymbol{\beta}}$, *obtained by solving* (9) *or* (10), *satisfies* $\sqrt{n}(\widehat{\boldsymbol{\beta}} - \boldsymbol{\beta}) \to N(\mathbf{0}, \mathbf{A}^{-1}\mathbf{B}\mathbf{A}^{-1^T})$ *in distribution when* $n \to \infty$, *where* $\mathbf{A}$ *and* $\mathbf{B}$ *are given in Supplementary Material* 4.4 (*Zhao et al.* (2024)).

Further, the estimator, $\widehat{\boldsymbol{\beta}}$, *obtained by solving* (10), *is semiparametrically efficient and satisfies*

$$\sqrt{n}(\widehat{\boldsymbol{\beta}} - \boldsymbol{\beta}) \to N\{\mathbf{0}, (E[\mathbf{S}_{\text{eff}}^{\otimes 2}\{\Delta, Z, \mathbf{X}, I(W \le Z), W I(W \le Z)\}])^{-1}\}$$

in distribution, where $\mathbf{S}_{\text{eff}}\{Z, \boldsymbol{\beta}^T\mathbf{X}, I(W \le Z), W I(W \le Z)\}$ *is given in* (6).

THEOREM 3. *Under the regularity conditions in Supplementary Material* 4.1 (*Zhao et al.* (2024)), *the nonparametric estimators* $\widehat{m}_N(t, \widehat{\boldsymbol{\beta}}^T\mathbf{X})$ *and* $\widehat{m}_T(t, \widehat{\boldsymbol{\beta}}^T\mathbf{X}, W)$ *satisfy*

$$\sqrt{nh}\{\widehat{m}_N(t, \widehat{\boldsymbol{\beta}}^T\mathbf{X}) - m_N(t, \boldsymbol{\beta}^T\mathbf{X})\} \to N\{0, \sigma_N^2(t, \boldsymbol{\beta}^T\mathbf{X})\},$$

$$\sqrt{nh}\{\widehat{m}_T(t, \widehat{\boldsymbol{\beta}}^T\mathbf{X}, W) - m_T(t, \boldsymbol{\beta}^T\mathbf{X}, W)\} \to N\{0, \sigma_T^2(t, \boldsymbol{\beta}^T\mathbf{X}, W)\}$$

in distribution for all t, W (*such that* $W < t$) *and* $\mathbf{X}$, *where* $\sigma_N^2(t, \boldsymbol{\beta}^T\mathbf{X})$ *and* $\sigma_T^2(t, \boldsymbol{\beta}^T\mathbf{X}, W)$ *are given in Supplementary Material* 4.5 (*Zhao et al.* (2024)).

5. Simulation. The section features four simulation studies for evaluating the finite sample performance of our method. For comparisons, we additionally implement a semiparametric proportional mean residual life model, denoted as "PM" (Chen and Cheng (2005)), which implicitly assumes $d = 1$:

Study 1: We generate event times with hazard functions of $\lambda_N(t, \boldsymbol{\beta}^T\mathbf{X}) = te^{\boldsymbol{\beta}^T\mathbf{X}}$ and $\lambda_T(t, \boldsymbol{\beta}^T\mathbf{X}, W) = \frac{10e^{\boldsymbol{\beta}^T\mathbf{X}+W}+1}{t+1}$ so that the true mean residual life is

$$m_N(t, \boldsymbol{\beta}^T\mathbf{X}) = e^{\frac{t^2}{2e^{\boldsymbol{\beta}^T\mathbf{X}}}} \Phi\left(-\frac{t}{\sqrt{e^{\boldsymbol{\beta}^T\mathbf{X}}}}\right)\sqrt{2\pi},$$

$$m_T(t, \boldsymbol{\beta}^T\mathbf{X}, W) = \frac{t+1}{10e^{\boldsymbol{\beta}^T\mathbf{X}+W}},$$

where Φ is the cumulative distribution function of the standard normal distribution. Each component of $\mathbf{X}$ is generated independently from the standard normal distribution, and W is generated independently from a uniform distribution over $[0, 10]$. We consider $d = 1$, $p = 9$ and set the true parameters to be $\boldsymbol{\beta} = (1, -0.6, 0.0, -0.3, -0.1, 0.0, 0.1, 0.3, -0.5)^T$. The sample size is $n = 300$, and we randomly assign one-third of samples to take the transplant.

Study 2: We generate event times with hazard functions of $\lambda_N(t, \boldsymbol{\beta}^T\mathbf{X}) = \frac{2t}{e^{\boldsymbol{\beta}^T\mathbf{X}+t^2}}$ and $\lambda_T(t, \boldsymbol{\beta}^T\mathbf{X}, W) = \phi\{\ln(t) - 3 - W/100 + 0.1(1 - \sqrt{2}\boldsymbol{\beta}^T\mathbf{X})^2\}/t[\Phi\{-\ln(t) + 3 + W/100 - \,$

$0.1(1 - \sqrt{2}\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X})^2\}]$ so that the true mean residual life is

$$m_N(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}) = \left(1 + \frac{t^2}{e^{\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}}}\right)\left\{\frac{\pi}{2} - \tan^{-1}\left(\frac{t}{e^{\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}}}\right)\right\},$$

$$m_T(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}, W) = \Phi\{-\ln(t) + 3 + W/100 - 0.1(1 - \sqrt{2}\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X})^2\}$$

$$\times \int_t^\infty \frac{1}{\Phi\{3 + W/100 - \ln(s) - 0.1(1 - \sqrt{2}\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X})^2\}}\, ds,$$

where ϕ is the probability density function of the standard normal distribution. Each component of $\mathbf{X}$ is generated independently from the standard normal distribution, and W is generated independently from uniform distribution over [0, 200]. We consider $d = 1$, $p = 9$ and set the true parameters to be $\boldsymbol{\beta} = (1, -0.6, 0, -0.3, -0.1, 0, 0.1, 0.3, -0.5)^{\mathrm{T}}$. The sample size is $n = 1000$, and we randomly assign one-third of samples to take the transplant.

Study 3: The hazard functions are $\lambda_N(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}) = t^{2/5}\sum_{i=1}^d e^{\boldsymbol{\beta}_i^{\mathrm{T}}\mathbf{X}}$ and $\lambda_T(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}, W) = t^{7/5}W\sum_{i=1}^d e^{\boldsymbol{\beta}_i^{\mathrm{T}}\mathbf{X}}$, with the corresponding mean residual lives of

$$m_N(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}) = e^{\frac{5}{7}t^{7/5}\sum_{i=1}^d e^{\boldsymbol{\beta}_i^{\mathrm{T}}\mathbf{X}}}\int_t^\infty e^{-\frac{5}{7}s^{7/5}\sum_{i=1}^d e^{\boldsymbol{\beta}_i^{\mathrm{T}}\mathbf{X}}}\, ds,$$

$$m_T(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}, W) = e^{\frac{5}{12}t^{12/5}\sum_{i=1}^d e^{\boldsymbol{\beta}_i^{\mathrm{T}}\mathbf{X}}}W\int_t^\infty e^{-\frac{5}{12}s^{12/5}\sum_{i=1}^d e^{\boldsymbol{\beta}_i^{\mathrm{T}}\mathbf{X}}}\, ds.$$

Each component of $\mathbf{X}$ is generated independently from the standard normal distribution. The waiting time W is generated independently from a uniform distribution over $(0, 1)$. We consider $d = 2$, $p = 6$ and set the true parameters to be $\boldsymbol{\beta} = (\boldsymbol{\beta}_{\cdot 1}, \boldsymbol{\beta}_{\cdot 2}) = ((1, 0, -0.65, -0.5, -0.25, 0.25)^{\mathrm{T}}, (0, 1, -0.5, 0.5, -0.4, 0.25)^{\mathrm{T}})^{\mathrm{T}}$. The sample size is $n = 2000$, and we randomly assign around one-third of samples to take the transplant.

Study 4: This setting mimics the real data application. The hazards are set to be

$$\lambda_N(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}) = \frac{1}{200}e^{t/200 + \arctan(\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}) + \pi/2} - \frac{1}{200},$$

and

$$\lambda_T(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}, W) = \frac{1}{300}e^{t/300 + \arctan(\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X} - W/5 + 10) + \pi/2} - \frac{1}{300},$$

with the corresponding mean residual lives of

$$m_N(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}) = 200e^{-t/200 - \arctan(\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}) - \pi/2},$$

$$m_T(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{X}, W) = 300e^{-t/300 - \arctan(\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X} - W/5 + 10) - \pi/2}.$$

We consider $d = 1$, $p = 9$ and set the true parameters to be $\boldsymbol{\beta} = (0.4, 1, -0.4, -1.50, -1.1, 1.4, -0.1, -0.7)^{\mathrm{T}}$. The transplantation time W is generated from the uniform distribution on $(0, \max(T_N))$. The sample size is $n = 2000$ with a censoring rate of 26%, and about half of the samples receive the transplantation during followup. Study 4 mimics the features of real data that the mean residual life functions are decreasing gradually as t increases. The transplant group accounts for W: the improvement $m_T(t - W, \mathbf{X}, W) - m_N(t, \mathbf{X})$ is negative, when W is close to 0, and approaches 0 positively as W increases.

The results for the estimation of $\boldsymbol{\beta}$ under Study 1 are given in Table 1 with three censoring rates, 0%, 20% and 40%. The proposed method has much smaller biases and standard deviations, whereas "PM" is biased with larger standard deviations. The performances of all of the estimators deteriorate when the censoring rate increases, though our method still outperforms

TABLE 1

Results of Study 1, based on 1000 *simulations with sample size* 300. *"Prop." is the semiparametric method;* *"PM" is the proportional mean residual life method. "emp sd" is the sample standard deviation of the corresponding estimators; "est sd" is the estimated standard deviation; "CP" is the estimated coverage probability of confidence intervals*

		β_2	β_3	β_4	β_5	β_6	β_7	β_8	β_9
	Truth	-0.6	0.0	-0.3	-0.1	0.0	0.1	0.3	-0.5
					No censoring				
Prop.	point estimate	-0.597	0.002	-0.290	-0.096	0.000	0.073	0.302	-0.504
	emp sd	0.229	0.442	0.180	0.438	0.437	0.437	0.171	0.206
	est sd	0.164	0.474	0.166	0.470	0.474	0.469	0.166	0.165
	CP(%)	88.8	96.2	94.4	96.0	95.8	96.1	94.9	91.2
PM	point estimate	0.442	-0.978	5.697	-20.47	0.986	-13.60	5.893	-3.780
	emp sd	57.8	95.11	155.9	583.0	36.7	352.5	212.5	156.5
					20% censoring				
Prop.	point estimate	-0.590	-0.003	-0.289	-0.086	0.007	0.101	0.289	-0.486
	emp sd	0.178	0.379	0.153	0.373	0.379	0.368	0.148	0.165
	est sd	0.156	0.406	0.146	0.404	0.407	0.406	0.145	0.152
	CP(%)	92.8	96.7	94.1	96.7	97.1	96.9	95.6	94.8
PM	point estimate	-0.774	0.067	-0.236	-0.027	0.150	0.176	0.339	-0.577
	emp sd	2.235	3.794	1.380	3.693	5.911	3.563	1.570	3.981
					40% censoring				
Prop.	point estimate	-0.518	0.020	-0.260	-0.079	0.020	0.088	0.266	-0.434
	emp sd	0.168	0.368	0.136	0.368	0.387	0.362	0.142	0.159
	est sd	0.149	0.392	0.140	0.396	0.391	0.389	0.140	0.144
	CP(%)	89.0	96.9	94.7	97.4	96.0	96.2	94.9	89.9
PM	point estimate	7.493	-7.316	-1.349	9.838	-21.588	-19.11	2.057	5.720
	emp sd	262.6	160.8	116.7	367.1	570.9	762.8	63.4	185.9

the others. We also demonstrate the true and error plots in Supplementary Material Figure S1–S3 (Zhao et al. (2024)) and show that our method fares well for estimating $m(t, \beta^T \mathbf{x})$ when t and $\beta^T \mathbf{x}$ are not too extreme. The contour plots reveal that bias increases as censoring rate increases and the estimation deteriorates when t is large. These results show an overall satisfactory performance of our semiparametric method. Figures S1–S3 in the Supplementary Material (Zhao et al. (2024)) reveal that the performance of our method is better when t is in the interior of the range because more observations are available for the local estimation, as opposed to a larger t with fewer observations available. In contrast, regardless of the magnitude of t, the mean residual life function, estimated by "PM," is severely biased, as shown in the last two rows from Figures S1–S3 (Supplementary Material (Zhao et al. (2024))). This is because this model assume a predetermined functional form of the mean residual life, which in this case is misspecified.

Tables 2 and 3 report the results of Studies 2 and 3 related to $\widehat{\beta}$, respectively. We also provide the error plots of $\widehat{m}(t, \beta^T \mathbf{x}) - m(t, \beta^T \mathbf{x})$ in Study 2 using a contour plot in Supplementary Material Figures S4–S6 (Zhao et al. (2024)). The proposed method performs better than the competitor. For Study 3 we provide the error plots of $\widehat{m}(t, \beta_1^T \mathbf{x}, \beta_2^T \mathbf{x}) - m(t, \beta_1^T \mathbf{x}, \beta_2^T \mathbf{x})$ fixed at $\beta_1^T \mathbf{x} = 0$ and $\beta_2^T \mathbf{x} = 0$ in Supplementary Material Figures S7 and S8 (Zhao et al. (2024)). Similar to the conclusion in the first simulation study, the performance of estimating β by our proposed estimator is satisfactory. The performance of the mean residual life estimation is better when t is smaller, deteriorates when t and $\beta^T \mathbf{x}$ becomes extreme and is better for smaller censoring rates.

TABLE 2

Results of Study 2, based on 1000 *simulations with sample size* 1000. *"Prop." is the semiparametric method; "PM" is the proportional mean residual life method. "emp sd" is the sample standard deviation of the corresponding estimators; "est sd" is the estimated standard deviation; "CP" is the estimated coverage probability of confidence intervals*

		β_2	β_3	β_4	β_5	β_6	β_7	β_8	β_9
	Truth	−0.60	0.00	−0.30	−0.10	0.00	0.10	0.30	−0.50
					No censoring				
Prop.	point estimate	−0.611	0.002	−0.308	−0.101	−0.005	0.101	0.310	−0.505
	emp sd	0.140	0.106	0.114	0.104	0.106	0.104	0.114	0.127
	est sd	0.135	0.118	0.122	0.118	0.118	0.118	0.122	0.129
	CP(%)	95.0	97.4	97.5	98.1	97.4	97.6	97.3	95.8
PM	point estimate	−0.601	0.003	−0.301	−0.099	0.006	0.096	0.300	−0.506
	emp sd	0.069	0.083	0.073	0.074	0.083	0.088	0.097	0.084
					20% censoring				
Prop.	point estimate	−0.596	0.003	−0.306	−0.100	0.001	0.094	0.303	−0.499
	emp sd	0.140	0.116	0.126	0.113	0.109	0.110	0.123	0.137
	est sd	0.135	0.119	0.123	0.119	0.119	0.119	0.123	0.130
	CP(%)	94.7	95.8	94.4	96.5	97.0	96.1	96.0	94.5
PM	point estimate	−0.604	0.000	−0.305	−0.114	−0.023	0.092	0.299	−0.501
	emp sd	0.146	0.380	0.121	0.355	0.373	0.384	0.132	0.133
					40% censoring				
Prop.	point estimate	−0.596	0.001	−0.300	−0.098	−0.004	0.098	0.295	−0.498
	emp sd	0.156	0.129	0.136	0.131	0.125	0.127	0.140	0.148
	est sd	0.147	0.129	0.134	0.130	0.129	0.130	0.134	0.142
	CP(%)	95.1	95.0	95.4	94.8	95.9	95.6	93.5	93.9
PM	point estimate	−0.553	0.495	−0.242	0.220	0.114	−0.216	0.379	−0.565
	emp sd	1.805	15.895	2.105	10.373	4.706	10.316	2.535	1.833

TABLE 3

Results of Study 3, based on 1000 *simulations with sample size* 2000. *"emp sd" is the sample standard deviation of the corresponding estimators; "est sd" is the estimated standard deviation; "CP" is the estimated coverage probability of confidence intervals*

	β_{31}	β_{41}	β_{51}	β_{61}	β_{32}	β_{42}	β_{52}	β_{62}
Truth	−0.65	−0.50	−0.25	0.25	−0.50	0.40	−0.40	0.25
				No censoring				
point estimate	−0.662	−0.551	−0.237	0.253	−0.492	0.465	−0.407	0.251
emp sd	0.152	0.117	0.136	0.129	0.169	0.121	0.137	0.129
est sd	0.139	0.125	0.145	0.146	0.147	0.131	0.152	0.154
CP(%)	91.3	93.4	95.5	96.1	89.9	93.5	96.6	97.8
				20% censoring				
point estimate	−0.608	−0.401	−0.252	0.238	−0.480	0.301	−0.363	0.236
emp sd	0.105	0.097	0.097	0.091	0.110	0.098	0.098	0.090
est sd	0.103	0.094	0.107	0.107	0.108	0.098	0.111	0.112
CP(%)	93.4	81.2	94.9	96.1	93.1	81.8	95.9	98.0
				40% censoring				
point estimate	−0.587	−0.420	−0.234	0.227	−0.456	0.316	−0.357	0.228
emp sd	0.084	0.071	0.080	0.073	0.089	0.082	0.078	0.074
est sd	0.092	0.083	0.092	0.093	0.098	0.087	0.097	0.098
CP(%)	93.3	87.3	97.5	97.7	95.2	85.4	97.3	98.1

		β_2 0.4	β_3 1	β_4 −0.4	β_5 −1.50	β_6 −1.1	β_7 1.4	β_8 −0.1	β_9 −0.7
Prop.	point estimate	0.409	0.912	−0.396	−1.263	−0.945	1.344	−0.109	−0.606
	emp sd	0.300	0.638	0.427	1.191	0.647	0.647	0.312	0.478
	est sd	0.279	0.776	0.473	1.225	0.769	0.763	0.467	0.519
	CP(%)	90.3	96.5	97.5	94.8	95.7	97.4	97.6	92.0
PM	point estimate	0.646	0.950	0.205	−0.776	−0.303	0.790	1.557	−0.090
	emp sd	22.847	6.882	2.545	3.545	1.879	4.259	8.725	1.556

The results for Study 4 are presented in Table 4, which displays the estimated vector $\widehat{\boldsymbol{\beta}}$ for both methods. Notably, the PM method exhibits a significantly larger bias compared to our method. We also assess the error of $\widehat{m}_T(t − w, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{x}, w) − \widehat{m}_N(t, \boldsymbol{\beta}^{\mathrm{T}}\mathbf{x})$ using a contour plot in Supplementary Material Figure S9 (Zhao et al. (2024)). Our proposed method outperforms the competitor across various scenarios. This difference in performance is particularly evident when $\boldsymbol{\beta}^{\mathrm{T}}\mathbf{X} > 0$, where the PM method struggles to accurately estimate the mean residual life function of the transplanted objects. This discrepancy can be attributed to the PM method's limited ability to handle the nonlinear structure inherent in the mean residual life function.

Finally, we have assessed the use of the validated information criterion (VIC) (Ma and Zhang (2015)) for determining the number of indices, d, of the dimension reduction model in these four study settings; the d with the smallest VIC value would be selected. In Study 1, VIC selects d with an accuracy of 100% under all three censoring rates, whereas the accuracies of selecting d via VIC are 97.1%, 100% and 100% in Study 2 and are 100%, 99.8% and 99.8% in Study 3, respectively, corresponding to the censoring rates of 0%, 20% and 40%. Moreover, the accuracy of determining d via VIC in Study 4 is 97.8%. These high accuracies validate the utility of using VIC to select d across the examined settings.

6. Analysis of the kidney transplant data. We apply the proposed method to analyze a kidney transplant data set from the U.S. Scientific Registry of Transplant Recipients (SRTR) mentioned in the Introduction. Briefly, the registry is maintained by the United Network for Organ Sharing and Organ Procurement and Transplantation Network (UNOS/OPTN) and includes all waitlisted kidney transplant candidates and transplant recipients in the U.S. (https://unos.org/). For assessing possible benefits of transplantation, we use the residual life to estimate how much longer a patient can survive if she or he receives a transplant than otherwise.

To avoid confounding cohort effects and also to have a sufficiently long follow-up, we focus on the patients who were waitlisted in the same year of 2011. There were 43,140 patients in this cohort with an average follow-up of 907 days after waitlisting. During the follow-up, a total of 22,183 patients received kidney transplants. The response variable is the survival time in days (T_i) starting from waitlisting. Among patients who got a transplantation, 5.86% of the observations were censored, and the censoring rate was 26.43% among those without a transplantation. The covariates $\mathbf{X}$ included in our analysis were gender (X_1), race (X_2), max cold ischemia time (X_3), insurance coverage (X_4), body mass index (X_5), diagnosis type (X_6), peak PRA/CPRA (X_7), previous malignancy status (X_8) and diabetes indicator (X_9), all of which were used for computing the EPTS score (Time (2012)). The waiting time W is also considered in our model, as proposed in (1) and (2). Our analytical goal was to use model (2)

	$\widehat{\beta}_2$	$\widehat{\beta}_3$	$\widehat{\beta}_4$	$\widehat{\beta}_5$	$\widehat{\beta}_6$	$\widehat{\beta}_7$	$\widehat{\beta}_8$	$\widehat{\beta}_9$
est.	−0.097	−0.003	−0.174	−0.029	−0.119	0.030	−0.162	0.004
s.d.	0.011	0.007	0.010	0.007	0.009	0.005	0.016	0.011
p-value	0.000	0.866	0.000	0.073	0.000	0.000	0.000	0.008

to quantify the potential residual life increment if a patient receives a kidney transplant, given the covariate profile. The model mimics a real waitlisting to transplantation process by stipulating that all of the patients started by belonging in the nontransplant group, while those who got a transplantation were viewed as censored at transplantation; once transplanted, a patient would switch his or her membership to join the transplant group.

To proceed, we first determine the number of indices d using VIC (Ma and Zhang (2015)). In our analysis, $d = 1$ is chosen with the smallest VIC = 143.66, indicating a single index is sufficiently informative; see Table 5. Subsequently, we normalize the index vector by fixing the first component (gender) at 1, and report eight coefficient estimates. All of the covariates, except for the max cold ischemia time (X_3) and the body mass index (X_5), have significant effects on the mean residual life, which agrees with the previous studies (Friedman et al. (2003), Webster et al. (2017)).

The max cold ischemia time (X_3) that refers to the tolerable amount of time from when a kidney is removed from the donor to the time it is transplanted into the recipient. Although the max cold ischemia time reflects the patient's physiological conditions indirectly, it is not as significant as the real cold ischemia time in determining the postoperative risk (Iida et al. (2008), Kayler et al. (2011)). BMI (X_5) is commonly suggested as a "paradox" risk factor in the literature (Ahmadi et al. (2016), Kalantar-Zadeh et al. (2005)). A popular explanation is that the BMI cannot differentiate between fat and muscle; thus, high BMI patients may gain a survival advantage (Beddhu (2004), Mafra, Guebre-Egziabher and Fouque (2008)).

On the other hand, race (X_2) and insurance coverage (X_4) have significant impacts on survival. It has been widely accepted that race and insurance coverage are highly correlated with patients' socioeconomic status, which plays an crucial role in the choice of chronic kidney disease treatment, especially for the end-stage patients (Lewis et al. (2010), Muntner et al. (2012), Nicholas, Kalantar-Zadeh and Norris (2013), Webster et al. (2017)). The other significant variables are also known risk factors for the ESRD mortality in the literature (Kauffman et al. (2005), Kayler et al. (2011), Lim, Chapman and Wong (2015), Mehdi and Toto (2009), Pyram et al. (2012)).

Given a patient with characteristics $\mathbf{x}$, alive at time t and waiting time w, $\widehat{m}_T(t - w, \widehat{\boldsymbol{\beta}}^T \mathbf{x}, w) - \widehat{m}_N(t, \widehat{\boldsymbol{\beta}}^T \mathbf{x})$ provides an estimate of the patient's mean residual life improvement after receiving a kidney transplant at w. Because the difference is a function of t, $\widehat{\boldsymbol{\beta}}^T \mathbf{x}$ and w, we present the difference using various plots. Figure 1 plots contours that change with t and $\widehat{\boldsymbol{\beta}}^T \mathbf{x}$ at several fixed w values.

Several important observations can be made. First, with the waiting time being close to 0 in each panel of Figure 1, kidney transplant led to less survival gains compared to dialysis treatment, possibly because patients transplanted without waiting were likely to be high-risk patients and postoperative complications, such as cardiovascular and urological complications, increase mortality risk among them (den Dekker et al. (2020), Rahnemai-Azar, Gilchrist and Kayler (2015)). Second, as the waiting time w increases, kidney transplant could result in a reasonably larger improvement compared to dialysis. This is because these patients tended

FIG. 1.   *Mean residual life improvement from UNOS/OPTN data. Panels from left to right:* $\boldsymbol{\beta}^T\mathbf{x} = -0.8, 0, 0.8$.

to be more stable, allowing kidney transplant to provide a notable survival advantage (Bui, Kilambi and Mehrotra (2019), Ingsathit et al. (2013), Schold et al. (2014)). Moreover, with t and w fixed, complex relationships existed between the patient's index value $\boldsymbol{\beta}^T\mathbf{x}$ and the survival improvement. The improvement is larger at $\boldsymbol{\beta}^T\mathbf{x} = 0$ than that at $\boldsymbol{\beta}^T\mathbf{x} = -0.8, 0.8$. It is very likely that large or small values of $\boldsymbol{\beta}^T\mathbf{x}$ were resulted by extreme health conditions which led to the worse improvement. Thus, this index in general measured patients' overall health condition.

Figures 2–4 further reveal the mean residual life improvement stratified by gender (X_1), race (X_2) and insurance coverage (X_4) at different values of $\boldsymbol{\beta}^T\mathbf{x}$. Several inequalities are noteworthy. First, patients with private insurance performed better than those with public insurance in most of cases, possibly due to socioeconomic status differences and the affordability for disease maintenance and treatment (Goldfarb-Rumyantzev et al. (2006), Nicholas, Kalantar-Zadeh and Norris (2015)). Second, the life gains were not very similar across male and female patients, especially the patterns differed between them. Females tended to have


FIG. 2.   *Mean residual life improvement from UNOS/OPTN data. Representative strata by race, gender and insurance status with minimum* $\boldsymbol{\beta}^T\mathbf{x}$ *per stratum.*

FIG. 3. *Mean residual life improvement from UNOS/OPTN data. Representative strata by race, gender and insurance status with median* $\boldsymbol{\beta}^{\mathrm{T}}\mathbf{x}$ *per stratum.*

life gains positively related to the index; in contrast, males tended to have higher residual life gains at small absolute index. It is likely that heterogeneous kidney disease progression rates and lifestyles might lead to the pattern discrepancy (Baylis (2009), Okada et al. (2014), Pscheidt et al. (2015)), though the negligible difference in quantity between genders exempli-

FIG. 4. *Mean residual life improvement from UNOS/OPTN data. Representative strata by race, gender, and insurance status with maximum* $\boldsymbol{\beta}^{\mathrm{T}}\mathbf{x}$ *per stratum.*

fied the "canceled survival advantage between genders" phenomenon (Carrero (2010), Cobo et al. (2016), Øien et al. (2006)). More detailed illustrations can be found in Figures S10–S12, Supplementary Material (Zhao et al. (2024)).

Survival gains of African Americans with public insurance were not monotonically related to the index regardless of gender, given t; further, it was observed that African–American females experienced greater life expansion compared to their male counterparts. Interestingly, we found the survival gains of African Americans were comparable with those of non-Hispanic Whites, even though these two racial groups had very different mortality among the general population (Lewis et al. (2010)). However, the African–American groups exhibited markedly different indices, compared to the non-Hispanic white groups, possibly due to lifestyles and lack of access to healthcare among those groups (Fedewa et al. (2014), Kasiske, London and Ellison (1998), Nicholas, Kalantar-Zadeh and Norris (2013)).

The Hispanic patients displayed consistent patterns in relation to their insurance type. Notably, there was minimal improvement in life gains when w was less than 500 and when $\boldsymbol{\beta}^T\mathbf{x} > -1.2$. However, at $\boldsymbol{\beta}^T\mathbf{x} = -1.8$, life gains showed a notable increase as w increased. The most significant decrease in life gains was observed under specific conditions: when t and w were small, and $\boldsymbol{\beta}^T\mathbf{x} < -1.5$. These trends held true for both genders and across different insurance types.

Among the Asian patients, a distinct pattern emerged in life gains with respect to t and w. Initially, life gains exhibited a rising trend, followed by a subsequent decline, with fluctuations observed along these dimensions. However, when $\boldsymbol{\beta}^T\mathbf{x} < 0$, the alterations in life gains were less pronounced. Remarkably, the impact of insurance type on survival outcomes varied between genders. For the female patients, the choice between private and public insurance did not yield significantly divergent survival gains. Conversely, among the male patients, private insurance demonstrated a better outcomes when compared to public insurance.

7. Discussion. Addressing a severe shortage of organs that are needed to sustain ESRD patients' life, this work aims to design a feasible strategy to increase the potential efficiency brought by each available kidney. Instead of evaluating the patients' expected survival time, as is done in the literature, we consider the potential residual life prolonged by kidney transplant. By comparing patients' expected residual life with and without transplant, we use their difference to gauge the potential benefit gained from the transplant; patients with larger differences may have a higher priority for organ allocations than those with smaller values. As the primary purpose of the project is to improve the donor distribution strategy by assessing the posttransplantation performance, particularly with very limited organ donations, rendering the measurement of the entire lifespan is likely to be more pertinent (Assfalg et al. (2020)) than focusing solely on a limited portion of future life, which the restricted mean survival time (RMST) is designed for. In addition, the choice of the length of the follow-up window may complicate the organ distribution strategy. Therefore, we opt for the proposed model, which is established on the premise of improving the overall residual life.

A natural extension of our model is to compute the causal effect between two groups. In the absence of a strong confounder "age," it is impossible to draw causal conclusion in this study. However, our comparison between two groups has a capability to analyze the causality as long as all confounders are included. On the other hand, our model compares the transplant cohort to a special case of the nontransplant cohort in which the transplantation would never happen in the future. A more general model will be studied in the future that transplant occurred at any time. Therefore, excepting comparing the mean residual life, many other quantities such as all-cause survivals and hazard ratio will be considered (Aalen, Cook and Røysland (2015), Andersen, Syriopoulou and Parner (2017), Syriopoulou, Rutherford and Lambert (2020)).

Our semiparametric regression model of mean residual life relaxes the parametric assumptions on the dependence of mean residual life on covariates and how long a patient has lived. To strike a balance between interpretation and flexibility, our procedure enables one to reduce the covariate dimensions from p to d: when $d = 1$, the model falls to the single index model, while $d = p$ corresponds to a completely nonparametric model. We suggest to use the validated information criterion (Ma and Zhang (2015)) to choose d, which seems to fare well in practice.

In our model, both the transplant and nontransplant groups are characterized by the same set of indices, denoted as $\boldsymbol{\beta}$, throughout the study. An alternative would be to conduct separate estimation processes to distinguish the effects of these indices on different transplantation statuses. While our method can accommodate this suggestion by applying the model separately to each group, this separation approach may imply independent progressions for the same patient before and after the transplant. This may be beyond the scope of our primary objective of consistently quantifying survival improvements. To estimate the mean residual life enhancement attributable to inherent factors which reflect patient functional status, we intend to treat each patient's progression as a cohesive whole. This seems reasonable in the realm of kidney transplantation, as studies showed that transplant does not interact significantly with patients' pre-operative functional status and is "associated with substantial improvement in all stages of functional capacity" (Ali et al. (2021)).

To ensure estimability, we have assumed the complete follow-up condition, which is reasonable in clinical studies with high event rates and long follow-up (Sun, Song and Zhang (2012)), such as in studies with advanced stage cancer patients (Chen et al. (2005)) and ESRD patients (Mansourvar, Martinussen and Scheike (2016)). Our data example features renal failure patients with a long follow-up, which may satisfy the assumption. We also acknowledge that, while the complete follow-up condition is a common assumption (Chen and Cheng (2005), Chen et al. (2005), Sun and Zhang (2009), Tsiatis (1990)), it incurs some limitations. For example, Ying (1993) pointed out that this assumption implies that the knowledge of the support is obtained in advance to assure a reasonable maximum follow-up time τ. Sun, Song and Zhang (2012), Chen and Cheng (2006) and Mansourvar, Martinussen and Scheike (2015) proposed various ways of selecting a reasonable τ, all requiring certain preknowledge. Due to these limitations, in Supplementary Material 5 (Zhao et al. (2024)), we further relax the complete follow-up condition, where we allow an unbounded support for the event time and only require a tail condition on the distribution similar to but weaker than the sub-Gaussian type. Finally, we are aware that the kidney transplant data from the U.S. SRTR may represent a biased sample; that is, the included patients were those with access to transplantation. In order to make results generalizable to a more general population, it is vital to take the probability of accessing transplantation into account. Estimation of this probability, however, is challenging because of many tangible and intangible factors involved in the process (Axelrod et al. (2008), Carrero et al. (2018), Kucirka, Purnell and Segev (2015), Weng et al. (2010)). More research is warranted.

SUPPLEMENTARY MATERIAL

Supplement (DOI: 10.1214/24-AOAS1887SUPP; .pdf). Regularity conditions, technical properties, lemmas and proofs.

REFERENCES

AALEN, O. O., COOK, R. J. and RØYSLAND, K. (2015). Does Cox analysis of a randomized survival study yield a causal treatment effect? *Lifetime Data Anal*. **21** 579–593. MR3397507 https://doi.org/10.1007/s10985-015-9335-y

AHMADI, S.-F., ZAHMATKESH, G., AHMADI, E., STREJA, E., RHEE, C. M., GILLEN, D. L., DE NICOLA, L., MINUTOLO, R., RICARDO, A. C. et al. (2016). Association of body mass index with clinical outcomes in non-dialysis-dependent chronic kidney disease: A systematic review and meta-analysis. *Cardiorenal Med*. **6** 37–49.

ALI, H., SOLIMAN, K., MOHAMED, M. M., RAHMAN, M., HERBERTH, J., FÜLÖP, T. and ELSAYED, I. (2021). Impact of kidney transplantation on functional status. *Ann. Med*. **53** 1303–1309.

ANDERSEN, P. K., BORGAN, Ø., GILL, R. D. and KEIDING, N. (1993). *Statistical Models Based on Counting Processes*. *Springer Series in Statistics*. Springer, New York. MR1198884 https://doi.org/10.1007/978-1-4612-4348-9

ANDERSEN, P. K., SYRIOPOULOU, E. and PARNER, E. T. (2017). Causal inference in survival analysis using pseudo-observations. *Stat. Med*. **36** 2669–2681. MR3670384 https://doi.org/10.1002/sim.7297

ASSFALG, V., SELIG, K., TOLKSDORF, J., VAN MEEL, M., DE VRIES, E., RAMSOEBHAG, A.-M., RAHMEL, A., RENDERS, L., NOVOTNY, A. et al. (2020). Repeated kidney re-transplantation—the Eurotransplant experience: A retrospective multicenter outcome analysis. *Transpl. Int*. **33** 617–631.

AXELROD, D. A., GUIDINGER, M. K., FINLAYSON, S., SCHAUBEL, D. E., GOODMAN, D. C., CHOBANIAN, M. and MERION, R. M. (2008). Rates of solid-organ wait-listing, transplantation, and survival among residents of rural and urban areas. *JAMA* **299** 202–207.

BAYLIS, C. (2009). Sexual dimorphism in the aging kidney: Differences in the nitric oxide system. *Nat. Rev. Nephrol*. **5** 384–396. https://doi.org/10.1038/nrneph.2009.90

BEDDHU, S. (2004). Hypothesis: The body mass index paradox and an obesity, inflammation, and atherosclerosis syndrome in chronic kidney disease. In *Seminars in Dialysis* **17** 229–232. Wiley, New York.

BICKEL, P. J., KLAASSEN, C. A. J., RITOV, Y. and WELLNER, J. A. (1993). *Efficient and Adaptive Estimation for Semiparametric Models*. *Johns Hopkins Series in the Mathematical Sciences*. Johns Hopkins Univ. Press, Baltimore, MD. MR1245941

BUI, K., KILAMBI, V. and MEHROTRA, S. (2019). Functional status-based risk-benefit analyses of high-KDPI kidney transplant versus dialysis. *Transplant. Int*. **32** 1297–1312. https://doi.org/10.1111/tri.13483

CARRERO, J. J. (2010). Gender differences in chronic kidney disease: Underpinnings and therapeutic implications. *Kidney Blood Press. Res*. **33** 383–392. https://doi.org/10.1159/000320389

CARRERO, J. J., HECKING, M., CHESNAYE, N. C. and JAGER, K. J. (2018). Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. *Nat. Rev. Nephrol*. **14** 151–164. https://doi.org/10.1038/nrneph.2017.181

CASELLA, G. and BERGER, R. L. (2001). *Statistical Inference*. Cengage Learning. MR1051420

CHADBAN, S. J., AHN, C., AXELROD, D. A., FOSTER, B. J., KASISKE, B. L., KHER, V., KUMAR, D., OBERBAUER, R., PASCUAL, J. et al. (2020). KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. *Transplantation* **104** S11–S103.

CHEN, Y. Q. (2007). Additive expectancy regression. *J. Amer. Statist. Assoc*. **102** 153–166. MR2345536 https://doi.org/10.1198/016214506000000870

CHEN, Y. Q. and CHENG, S. (2005). Semiparametric regression analysis of mean residual life with censored survival data. *Biometrika* **92** 19–29. MR2158607 https://doi.org/10.1093/biomet/92.1.19

CHEN, Y. Q. and CHENG, S. (2006). Linear life expectancy regression with censored data. *Biometrika* **93** 303–313. MR2278085 https://doi.org/10.1093/biomet/93.2.303

CHEN, Y. Q., JEWELL, N. P., LEI, X. and CHENG, S. C. (2005). Semiparametric estimation of proportional mean residual life model in presence of censoring. *Biometrics* **61** 170–178. MR2135857 https://doi.org/10.1111/j.0006-341X.2005.030224.x

COBO, G., HECKING, M., PORT, F. K., EXNER, I., LINDHOLM, B., STENVINKEL, P. and CARRERO, J. J. (2016). Sex and gender differences in chronic kidney disease: Progression to end-stage renal disease and haemodialysis. *Clin. Sci*. **130** 1147–1163. https://doi.org/10.1042/CS20160047

COSIO, F. G., ALAMIR, A., YIM, S., PESAVENTO, T. E., FALKENHAIN, M. E., HENRY, M. L., ELKHAMMAS, E. A., DAVIES, E. A., BUMGARDNER, G. L. et al. (1998). Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. *Kidney Inter*. **53** 767–772. https://doi.org/10.1046/j.1523-1755.1998.00787.x

DEN DEKKER, W. K., SLOT, M. C., KHO, M. M. L., GALEMA, T. W., VAN DE WETERING, J., BOERSMA, E. and ROODNAT, J. I. (2020). Predictors of postoperative cardiovascular complications up to 3 months after kidney transplantation. *Neth. Heart J*. **28** 202–209. https://doi.org/10.1007/s12471-020-01373-6

EVANS, R. W., MANNINEN, D. L., GARRISON, L. P. JR, HART, L. G., BLAGG, C. R., GUTMAN, R. A., HULL, A. R. and LOWRIE, E. G. (1985). The quality of life of patients with end-stage renal disease. *N. Engl. J. Med.* **312** 553–559.

FEDEWA, S. A., MCCLELLAN, W. M., JUDD, S., GUTIÉRREZ, O. M. and CREWS, D. C. (2014). The association between race and income on risk of mortality in patients with moderate chronic kidney disease. *BMC Nephrol.* **15** 1–9.

FENG, Y., HUANG, R., KAVANAGH, J., LI, L., ZENG, X., LI, Y. and FU, P. (2019). Efficacy and safety of dual blockade of the renin–angiotensin–aldosterone system in diabetic kidney disease: A meta-analysis. *Amer. J. Cardiovasc. Drugs* **19** 259–286.

FERRI, F. F. (2017). *Ferri's Clinical Advisor* 2018 *e-Book*: 5 *Books in* 1. Elsevier, MO.

FRIEDMAN, A. N., MISKULIN, D. C., ROSENBERG, I. H. and LEVEY, A. S. (2003). Demographics and trends in overweight and obesity in patients at time of kidney transplantation. *Amer. J. Kidney Dis.* **41** 480–487. https://doi.org/10.1053/ajkd.2003.50059

GOLDFARB-RUMYANTZEV, A. S., KOFORD, J. K., BAIRD, B. C., CHELAMCHARLA, M., HABIB, A. N., WANG, B.-J., LIN, S., SHIHAB, F. and ISAACS, R. B. (2006). Role of socioeconomic status in kidney transplant outcome. *Clin. J. Amer. Soc. Nephrol.* **1** 313–322. https://doi.org/10.2215/CJN.00630805

GORE, J. L., DANOVITCH, G. M., LITWIN, M. S., PHAM, P. T. and SINGER, J. S. (2009). Disparities in the utilization of live donor renal transplantation. *Amer. J. Transplant.* **9** 1124–1133. https://doi.org/10.1111/j.1600-6143.2009.02620.x

HALL, W. J. and WELLNER, J. (1981). Mean residual life. In *Statistics and Related Topics* (*Ottawa*, *Ont.*, 1980) 169–184. North-Holland, Amsterdam. MR0665274

HART, A., LENTINE, K., SMITH, J., MILLER, J., SKEANS, M., PRENTICE, M., ROBINSON, A., FOUTZ, J., BOOKER, S. et al. (2021). OPTN/SRTR 2019 annual data report: Kidney. *Amer. J. Transplant.* **21** 21–137.

HERNANDEZ, D., RUFINO, M., ARMAS, S., GONZALEZ, A., GUTIERREZ, P., BARBERO, P., VIVANCOS, S., RODRÍGUEZ, C., DE VERA, J. R. et al. (2006). Retrospective analysis of surgical complications following cadaveric kidney transplantation in the modern transplant era. *Nephrol. Dial. Transplant.* **21** 2908–2915.

HUMAR, A. and MATAS, A. J. (2005). Surgical complications after kidney transplantation. In *Seminars in Dialysis* **18** 505–510. Wiley, New York.

IIDA, S., KONDO, T., AMANO, H., NAKAZAWA, H., ITO, F., HASHIMOTO, Y. and TANABE, K. (2008). Minimal effect of cold ischemia time on progression to late-stage chronic kidney disease observed long term after partial nephrectomy. *Urology* **72** 1083–1088.

INGSATHIT, A., KAMANAMOOL, N., THAKKINSTIAN, A. and SUMETHKUL, V. (2013). Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: A systematic review and meta-analysis. *Transplantation* **95** 943–948. https://doi.org/10.1097/TP.0b013e3182848de2

JASSAL, S. V., SCHAUBEL, D. E. and FENTON, S. S. A. (2005). Baseline comorbidity in kidney transplant recipients: A comparison of comorbidity indices. *Amer. J. Kidney Dis.* **46** 136–142. https://doi.org/10.1053/j.ajkd.2005.03.006

JEONG, J.-H., JUNG, S.-H. and COSTANTINO, J. P. (2008). Nonparametric inference on median residual life function. *Biometrics* **64** 157–163, 323–324. MR2422830 https://doi.org/10.1111/j.1541-0420.2007.00826.x

JUNG, S.-H., JEONG, J.-H. and BANDOS, H. (2009). Regression on quantile residual life. *Biometrics* **65** 1203–1212. MR2756508 https://doi.org/10.1111/j.1541-0420.2009.01196.x

KALANTAR-ZADEH, K., ABBOTT, K. C., SALAHUDEEN, A. K., KILPATRICK, R. D. and HORWICH, T. B. (2005). Survival advantages of obesity in dialysis patients. *Amer. J. Clin. Nutr.* **81** 543–554.

KALBFLEISCH, J. D. and PRENTICE, R. L. (1980). *The Statistical Analysis of Failure Time Data*. Wiley Series in Probability and Mathematical Statistics. Wiley, New York. MR0570114

KASISKE, B. L., CANGRO, C. B., HARIHARAN, S., HRICIK, D. E., KERMAN, R. H., ROTH, D., RUSH, D. N., VAZQUEZ, M. A., WEIR, M. R. et al. (2001). The evaluation of renal transplantation candidates: Clinical practice guidelines. *Amer. J. Transplant.* **1** 3–95.

KASISKE, B. L., LONDON, W. and ELLISON, M. D. (1998). Race and socioeconomic factors influencing early placement on the kidney transplant waiting list. *J. Amer. Soc. Nephrol.* **9** 2142–2147. https://doi.org/10.1681/ASN.V9112142

KAUFFMAN, H. M., CHERIKH, W. S., MCBRIDE, M. A., CHENG, Y. A., DELMONICO, F. L. and HANTO, D. W. (2005). Transplant recipients with a history of a malignancy: Risk of recurrent and de novo cancers. *Transplant. Rev.* **19** 55–64.

KAYLER, L. K., MAGLIOCCA, J., ZENDEJAS, I., SRINIVAS, T. R. and SCHOLD, J. D. (2011). Impact of cold ischemia time on graft survival among ECD transplant recipients: A paired kidney analysis. *Amer. J. Transplant.* **11** 2647–2656. https://doi.org/10.1111/j.1600-6143.2011.03741.x

KUCIRKA, L. M., PURNELL, T. S. and SEGEV, D. L. (2015). Improving access to kidney transplantation: Referral is not enough. *JAMA* **314** 565–567.

LEWIS, J. et al. (2010). Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: A social and economic dilemma. *Clin. Nephrol.* **74** S72–7.

LIEM, Y. S., BOSCH, J. L., ARENDS, L. R., HEIJENBROK-KAL, M. H. and HUNINK, M. M. (2007). Quality of life assessed with the medical outcomes study short form 36-item health survey of patients on renal replacement therapy: A systematic review and meta-analysis. *Value Health* **10** 390–397.

LIEM, Y. S. and WEIMAR, W. (2009). Early living-donor kidney transplantation: A review of the associated survival benefit. *Transplantation* **87** 317–318. https://doi.org/10.1097/TP.0b013e3181952710

LIM, W. H., CHAPMAN, J. R. and WONG, G. (2015). Peak panel reactive antibody, cancer, graft, and patient outcomes in kidney transplant recipients. *Transplantation* **99** 1043–1050.

LIN, H., FEI, Z. and LI, Y. (2016). A semiparametrically efficient estimator of the time-varying effects for survival data with time-dependent treatment. *Scand. J. Stat.* **43** 649–663. MR3543315 https://doi.org/10.1111/sjos.12196

MA, Y. and WEI, Y. (2012). Analysis on censored quantile residual life model via spline smoothing. *Statist. Sinica* **22** 47–68. MR2933167 https://doi.org/10.5705/ss.2010.161

MA, Y. and YIN, G. (2010). Semiparametric median residual life model and inference. *Canad. J. Statist.* **38** 665–679. MR2753008 https://doi.org/10.1002/cjs.10076

MA, Y. and ZHANG, X. (2015). A validated information criterion to determine the structural dimension in dimension reduction models. *Biometrika* **102** 409–420. MR3371013 https://doi.org/10.1093/biomet/asv004

MA, Y. and ZHU, L. (2012). A semiparametric approach to dimension reduction. *J. Amer. Statist. Assoc.* **107** 168–179. MR2949349 https://doi.org/10.1080/01621459.2011.646925

MA, Y. and ZHU, L. (2013). Efficient estimation in sufficient dimension reduction. *Ann. Statist.* **41** 250–268. MR3059417 https://doi.org/10.1214/12-AOS1072

MAFRA, D., GUEBRE-EGZIABHER, F. and FOUQUE, D. (2008). Body mass index, muscle and fat in chronic kidney disease: Questions about survival. *Nephrol. Dial. Transplant.* **23** 2461–2466.

MAGULURI, G. and ZHANG, C.-H. (1994). Estimation in the mean residual life regression model. *J. Roy. Statist. Soc. Ser. B* **56** 477–489. MR1278221

MANSOURVAR, Z., MARTINUSSEN, T. and SCHEIKE, T. H. (2015). Semiparametric regression for restricted mean residual life under right censoring. *J. Appl. Stat.* **42** 2597–2613. MR3428833 https://doi.org/10.1080/02664763.2015.1043871

MANSOURVAR, Z., MARTINUSSEN, T. and SCHEIKE, T. H. (2016). An additive-multiplicative restricted mean residual life model. *Scand. J. Stat.* **43** 487–504. MR3503013 https://doi.org/10.1111/sjos.12187

MEHDI, U. and TOTO, R. D. (2009). Anemia, diabetes, and chronic kidney disease. *Diabetes Care* **32** 1320–1326. https://doi.org/10.2337/dc08-0779

MEIER-KRIESCHE, H.-U., PORT, F. K., OJO, O. A., AKINLOLU, O., RUDICH, S. M., HANSON, J. A., CIBRIK, D. M., LEICHTMAN, A. B. and KAPLAN, B. (2000). Effect of waiting time on renal transplant outcome. *Kidney Inter.* **58** 1311–1317.

MOLNAR, M. Z., CZIRA, M. E., RUDAS, A., UJSZASZI, A., HAROMSZEKI, B., KOSA, J. P., LAKATOS, P., BEKO, G., SARVARY, E. et al. (2011). Association between the malnutrition-inflammation score and post-transplant anaemia. *Nephrol. Dial. Transplant.* **26** 2000–2006.

MÜLLER, H.-G. and ZHANG, Y. (2005). Time-varying functional regression for predicting remaining lifetime distributions from longitudinal trajectories. *Biometrics* **61** 1064–1075. MR2216200 https://doi.org/10.1111/j.1541-0420.2005.00378.x

MUNTNER, P., NEWSOME, B., KRAMER, H., PERALTA, C. A., KIM, Y., JACOBS, D. R., KIEFE, C. I. and LEWIS, C. E. (2012). Racial differences in the incidence of chronic kidney disease. *Clin. J. Amer. Soc. Nephrol.* **7** 101–107. https://doi.org/10.2215/CJN.06450611

NICHOLAS, S. B., KALANTAR-ZADEH, K. and NORRIS, K. C. (2013). Racial disparities in kidney disease outcomes. In *Seminars in Nephrology* **33** 409–415. Elsevier, Amsterdam.

NICHOLAS, S. B., KALANTAR-ZADEH, K. and NORRIS, K. C. (2015). Socioeconomic disparities in chronic kidney disease. *Adv. Chronic Kidney Dis.* **22** 6–15. https://doi.org/10.1053/j.ackd.2014.07.002

OAKES, D. and DASU, T. (1990). A note on residual life. *Biometrika* **77** 409–410. MR1064816 https://doi.org/10.1093/biomet/77.2.409

OAKES, D. and DASU, T. (2003). Inference for the proportional mean residual life model. In *Crossing Boundaries: Statistical Essays in Honor of Jack Hall. Institute of Mathematical Statistics Lecture Notes—Monograph Series* **43** 105–116. IMS, Beachwood, OH. MR2125050 https://doi.org/10.1214/lnms/1215092393

ØIEN, C. M., REISÆTER, A. V., OS, I., JARDINE, A., FELLSTRÖM, B. and HOLDAAS, H. (2006). Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: Post hoc analysis of the ALERT study. *Clin. Transplant.* **20** 374–382.

OKADA, K., YANAI, M., TAKEUCHI, K., MATSUYAMA, K., NITTA, K., HAYASHI, K. and TAKAHASHI, S. (2014). Sex differences in the prevalence, progression, and improvement of chronic kidney disease. *Kidney Blood Press. Res.* **39** 279–288. https://doi.org/10.1159/000355805

PSCHEIDT, C., NAGEL, G., ZITT, E., KRAMAR, R., CONCIN, H. and LHOTTA, K. (2015). Sex- and time-dependent patterns in risk factors of end-stage renal disease: A large Austrian cohort with up to 20 years of follow-up. *PLoS ONE* **10** e0135052. https://doi.org/10.1371/journal.pone.0135052

PYRAM, R., KANSARA, A., BANERJI, M. A. and LONEY-HUTCHINSON, L. (2012). Chronic kidney disease and diabetes. *Maturitas* **71** 94–103. https://doi.org/10.1016/j.maturitas.2011.11.009

RAHNEMAI-AZAR, A. A., GILCHRIST, B. F. and KAYLER, L. K. (2015). Independent risk factors for early urologic complications after kidney transplantation. *Clin Transplant*. **29** 403–408. https://doi.org/10.1111/ctr.12530

RAMLAU-HANSEN, H. (1983). The choice of a kernel function in the graduation of counting process intensities. *Scand. Actuar. J*. **3** 165–182. MR0724596 https://doi.org/10.1080/03461238.1983.10408700

SALERNO, S., MESSANA, J. M., GREMEL, G. W., DAHLERUS, C., HIRTH, R. A., HAN, P., SEGAL, J. H., XU, T., SHAFFER, D. et al. (2021). COVID-19 risk factors and mortality outcomes among medicare patients receiving long-term dialysis. *JAMA Netw. Open* **4** e2135379–e2135379.

SARAN, R., LI, Y., ROBINSON, B., ABBOTT, K. C., AGODOA, L. Y., AYANIAN, J., BRAGG-GRESHAM, J., BALKRISHNAN, R., CHEN, J. L. et al. (2016). US renal data system 2015 annual data report: Epidemiology of kidney disease in the United States. *Amer. J. Kidney Dis*. **67**.

SCHOLD, J. D., BUCCINI, L. D., GOLDFARB, D. A., FLECHNER, S. M., POGGIO, E. D. and SEHGAL, A. R. (2014). Association between kidney transplant center performance and the survival benefit of transplantation versus dialysis. *Clin. J. Amer. Soc. Nephrol*. **9** 1773–1780. https://doi.org/10.2215/CJN.02380314

SUN, L., SONG, X. and ZHANG, Z. (2012). Mean residual life models with time-dependent coefficients under right censoring. *Biometrika* **99** 185–197. MR2899672 https://doi.org/10.1093/biomet/asr065

SUN, L. and ZHANG, Z. (2009). A class of transformed mean residual life models with censored survival data. *J. Amer. Statist. Assoc*. **104** 803–815. MR2541596 https://doi.org/10.1198/jasa.2009.0130

SYRIOPOULOU, E., RUTHERFORD, M. J. and LAMBERT, P. C. (2020). Marginal measures and causal effects using the relative survival framework. *Int. J. Epidemiol*. **49** 619–628. https://doi.org/10.1093/ije/dyz268

TIME, P. S. (2012). A guide to calculating and interpreting the estimated post-transplant survival (EPTS) score used in the Kidney Allocation System (KAS). Kidney 2.

TONELLI, M., WIEBE, N., KNOLL, G., BELLO, A., BROWNE, S., JADHAV, D., KLARENBACH, S. and GILL, J. (2011). Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes. *Amer. J. Transplant*. **11** 2093–2109. https://doi.org/10.1111/j.1600-6143.2011.03686.x

TSIATIS, A. A. (1990). Estimating regression parameters using linear rank tests for censored data. *Ann. Statist*. **18** 354–372. MR1041397 https://doi.org/10.1214/aos/1176347504

WAND, M. P. (1994). Fast computation of multivariate kernel estimators. *J. Comput. Graph. Statist*. **3** 433–445. MR1323051 https://doi.org/10.2307/1390904

WEBSTER, A. C., NAGLER, E. V., MORTON, R. L. and MASSON, P. (2017). Chronic kidney disease. *Lancet* **389** 1238–1252.

WENG, F. L., REESE, P. P., MULGAONKAR, S. and PATEL, A. M. (2010). Barriers to living donor kidney transplantation among black or older transplant candidates. *Clin. J. Amer. Soc. Nephrol*. **5** 2338–2347. https://doi.org/10.2215/CJN.03040410

WOLFE, R. A., ASHBY, V. B., MILFORD, E. L., OJO, A. O., ETTENGER, R. E., AGODOA, L. Y., HELD, P. J. and PORT, F. K. (1999). Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N. Engl. J. Med*. **341** 1725–1730. https://doi.org/10.1056/NEJM199912023412303

YING, Z. (1993). A large sample study of rank estimation for censored regression data. *Ann. Statist*. **21** 76–99. MR1212167 https://doi.org/10.1214/aos/1176349016

ZHAO, G., MA, Y., LIN, H. and LI, Y. (2024). Supplement to "Evaluation of transplant benefits with the U.S. Scientific Registry of Transplant Recipients by semiparametric regression of mean residual life." https://doi.org/10.1214/24-AOAS1887SUPP

ZHAO, G., MA, Y. and LU, W. (2022). Efficient estimation for dimension reduction with censored survival data. *Statist. Sinica* **32** 2359–2380. MR4485087 https://doi.org/10.5705/ss.202020.0404